Back to top
more

Werewolf Therapeutics (HOWL)

(Delayed Data from NSDQ)

$0.99 USD

0.99
11,587,027

+0.10 (11.10%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $0.97 -0.02 (-1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (157 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

by Zacks Equity Research

Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%

by Zacks Equity Research

The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 30% and 145.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 65.85% and 164.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 2.63% and 25.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of 0% and 14.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Buy Stocks for July 26th

by Zacks Equity Research

ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.

Zacks Equity Research

Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?

by Zacks Equity Research

In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.